| General Information |
| Business: |
We are a biopharmaceutical company focused on discovering, developing and commercializing novel cancer therapeutics. Our product candidates are directed against important mechanisms, or targets, known or believed to be involved in cancer. Tivozanib, our lead product candidate, is a novel, highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. Our clinical trials of tivozanib to date have demonstrated a favorable safety and efficacy profile for tivozanib. We have completed a successful 272-patient phase 2 clinical trial of tivozanib in patients with advanced renal cell cancer, or RCC. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
133 |
Founded: |
2001 |
|
| Contact Information |
| Address: |
75 Sidney Street, Cambridge, MA, 02139, US |
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 20.7 mil (last 12 months) |
|
| Net Income: |
$ (44.1) mil (last 12 months) |
|
|
|
| IPO Profile |
| Symbol: |
AVEO |
| Shares (millions): |
9.00 |
| Price Range: |
$9.00 - $10.00 |
| Est.$ Volume |
$ 81 mil |
| Manager / Joint Managers |
J.P.Morgan/ Morgan Stanley |
| Co Managers |
Leerink Swann/ Canaccord Adams |
| Expected to Trade |
3/12/2010 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
